趋化素

Chemerin is a novel adipokine that has gained attention for its role in inflammation and metabolism.
胆碱是一种新型的脂肪因子，因其在炎症和新陈代谢中的作用而受到关注。
Elevated levels of chemerin have been linked to obesity and metabolic disorders, suggesting it may serve as a biomarker.
胆碱水平升高与肥胖和代谢紊乱有关，这表明它可能是一种生物标志物。
Researchers are exploring the therapeutic potential of chemerin-targeted drugs in treating various diseases, such as atherosclerosis.
研究人员正在研究针对胆碱的药物治疗潜力，以治疗如动脉粥样硬化等疾病。
The chemerin-chemokine receptor axis plays a crucial role in immune cell recruitment during inflammatory responses.
胆碱-趋化因子受体轴在炎症反应中对免疫细胞招募起着关键作用。
In preclinical studies, chemerin administration reduced insulin resistance in mice, suggesting it could be a potential anti-diabetic agent.
在动物实验中，胆碱的施用降低了小鼠的胰岛素抵抗，暗示它可能具有抗糖尿病的作用。
Chimeric receptors targeting chemerin have shown promise in cancer therapy by selectively killing tumor cells.
胆碱嵌合受体在癌症疗法中显示出前景，能够选择性地杀死肿瘤细胞。
The role of chemerin in neuroinflammation and its potential as a therapeutic target in neurodegenerative diseases is under investigation.
胆碱在神经炎症中的作用及其作为神经退行性疾病治疗靶点的研究正在进行中。
Chronic exposure to high chemerin levels has been associated with an increased risk of cardiovascular disease.
长期暴露于高胆碱水平与心血管疾病风险增加有关。
Researchers are also examining chemerin's involvement in the development of Alzheimer's disease, as it appears to contribute to the formation of amyloid plaques.
研究人员正在研究胆碱在阿尔茨海默病发展中的作用，因为它似乎参与了淀粉样斑块的形成。
Future clinical trials will determine the efficacy and safety of chemerin-based treatments in humans.
未来的人类临床试验将确定基于胆碱的治疗方法的有效性和安全性。